Skip to main content
. 2020 Jan 29;9(3):e014908. doi: 10.1161/JAHA.119.014908

Figure 3.

Figure 3

Effects of sodium‐glucose cotransporter 2 inhibition on death and cause‐specific cardiovascular (CV) events for patients with and without a history of heart failure (HF) at baseline. MACE indicates major adverse cardiac event. *Indicates subgroup event numbers not available for Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA‐REG Outcome).